One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
A Step toward Interoperability of Health IT
David Blumenthal, M.D., M.P.P.
doi : 10.1056/NEJMp2213873
A Covid-19 Milestone Attained — A Correlate of Protection for Vaccines
Peter B. Gilbert, Ph.D., Ruben O. Donis, Ph.D., Richard A. Koup, M.D., Youyi Fong, Ph.D., Stanley A. Plotkin, M.D., and Dean Follmann, Ph.D.
doi : 10.1056/NEJMp2211314
Weight and Health — Pathophysiology and Therapies
Louis J. Aronne, M.D., Sarah Bramblette, Amber Huett-Garcia, Julie R. Ingelfinger, M.D., Ania M. Jastreboff, M.D., Ph.D., Sriram Machineni, M.D., Ph.D., Nikki Massie, and Clifford J. Rosen, M.D.
doi : 10.1056/NEJMp2214423
Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa
Shireen V. Guide, M.D., Mercedes E. Gonzalez, M.D., I. Sinem Bağcı, M.D., Brittani Agostini, B.S.N., Hubert Chen, M.D., Gloria Feeney, B.S., Molly Steimer, B.S., Binoy Kapadia, B.S., Kunju Sridhar, Ph.D., Lori Quesada Sanchez, B.S., Franshesca Gonzalez, B.S., Matthew Van Ligten, B.S.,
doi : 10.1056/NEJMoa2206663
Dystrophic epidermolysis bullosa is a rare genetic blistering skin disease caused by mutations in COL7A1, which encodes type VII collagen (C7). Beremagene geperpavec (B-VEC) is a topical investigational herpes simplex virus type 1 (HSV-1)–based gene therapy designed to restore C7 protein by delivering COL7A1.
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Michael J. Dickinson, M.B., B.S., D.Med.Sc., Carmelo Carlo-Stella, M.D., Franck Morschhauser, M.D., Ph.D., Emmanuel Bachy, M.D., Ph.D., Paolo Corradini, M.D., Gloria Iacoboni, M.D., Cyrus Khan, M.D., Tomasz Wróbel, M.D., Fritz Offner, M.D., Ph.D., Marek Trněný, M.D., Shang-Ju Wu, M.D., Ph.D., Guillaume Cartron, M.D., Ph.D.,
doi : 10.1056/NEJMoa2206913
The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. Glofitamab is a bispecific antibody that recruits T cells to tumor cells.
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Ajai Chari, M.D., Monique C. Minnema, M.D., Jesus G. Berdeja, M.D., Albert Oriol, M.D., Ph.D., Niels W.C.J. van de Donk, M.D., Ph.D., Paula RodrÃguez-Otero, M.D., Ph.D., Elham Askari, M.D., MarÃa-Victoria Mateos, M.D., Ph.D., Luciano J. Costa, M.D., Ph.D., Jo Caers, M.D., Ph.D., Raluca Verona, Ph.D., Suzette Girgis, Ph.D.,
doi : 10.1056/NEJMoa2204591
G protein–coupled receptor, family C, group 5, member D (GPRC5D) is an orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody against CD3 and GPRC5D, redirects T cells to mediate killing of GPRC5D-expressing myeloma cells.
Once-Weekly Semaglutide in Adolescents with Obesity
Daniel Weghuber, M.D., Timothy Barrett, Ph.D., Margarita Barrientos-Pérez, M.D., Inge Gies, Ph.D., Dan Hesse, Ph.D., Ole K. Jeppesen, M.Sc., Aaron S. Kelly, Ph.D., Lucy D. Mastrandrea, M.D., Rasmus Sørrig, Ph.D., and Silva Arslanian, M.D. for the STEP TEENS Investigators*
doi : 10.1056/NEJMoa2208601
A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment of the drug in adolescents has been lacking.
Skin Necrosis after Transarterial Chemoembolization
Myriam Viedma-Martinez, M.D., and Isabel Villegas Romero, M.D.
doi : 10.1056/NEJMicm2205333
Hereditary Geniospasm
Toon Dominicus, M.D., and Stephanie De Rechter, M.D., Ph.D.
doi : 10.1056/NEJMicm2102977
Case 38-2022: A 21-Year-Old Woman with Fatigue and Weight Gain
Allison Kimball, M.D., Madeleine Sertic, M.B., B.Ch., Philip J. Saylor, M.D., Sophia C. Kamran, M.D., and Baris Boyraz, M.D., Ph.D.
doi : 10.1056/NEJMcpc2201250
The Coming of Age of Topical Gene Therapy for Dystrophic Epidermolysis Bullosa
David V. Schaffer, Ph.D.
doi : 10.1056/NEJMe2212899
Topical Gene Therapy for Epidermolysis Bullosa
Aimee S. Payne, M.D., Ph.D.
doi : 10.1056/NEJMe2213203
Bispecific Antibodies in Lymphoma — Another Win for T Cells
Nancy L. Bartlett, M.D.
doi : 10.1056/NEJMe2212732
The Expanding Clinical Role of Bifunctional Antibodies
Dan L. Longo, M.D.
doi : 10.1056/NEJMe2208708
Audio Interview: Applying New Studies of Mpox and Ebola to Covid-19
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2216014
Click Here for Better Chemistry
Brian M. Zeglis, Ph.D., and Jason S. Lewis, Ph.D.
doi : 10.1056/NEJMcibr2213596
Tecovirimat for Monkeypox in Central African Republic under Expanded Access
doi : 10.1056/NEJMc2210015
